Page 38 - ARNM-1-1

Advances in Radiotherapy
& Nuclear Medicine SIR-spheres Y-90 resin microspheres for HCC treatment

Table 4. Adverse events within 6 months of SIRT
System organ class Preferred term Study participants (n=30)
Number of adverse events Number of participants n a % b
All 43 19 63.3
Gastrointestinal disorders All 23 13 43.3
Abdominal distention 1 1 3.3
Abdominal pain 11 11 36.7
Gastritis 1 1 3.3
Nausea 2 2 6.6
Pain in the right lumbar region 1 1 3.3
Pain in the right upper quadrant 2 2 6.6
Vomiting 5 5 16.7
General disorders and administration site All 4 4 13.3
conditions Exhaustion 1 1 3.3
Fatigue 1 1 3.3
Fever 1 1 3.3
Weight loss 1 1 3.3
Hepatobiliary disorders All 1 1 3.3
Hepatic dysfunction 1 1 3.3
Investigations All 4 4 13.3
Elevated liver enzymes 2 2 6.6
Decreased platelet count 2 2 6.6
Metabolism and nutrition disorders All 2 2 6.6
Anorexia 2 2 6.6
Neoplasms: benign, malignant, and unspecified All 6 6 20
(including cysts and polyps) Lung metastasis 2 2 6.6
Lymph nodes metastasis 1 1 3.3
Progressive cirrhosis 1 1 3.3
Progressive disease 1 1 3.3
Abdominal nodal metastasis 1 1 3.3
Respiratory, thoracic, and mediastinal disorders All 2 2 6.6
Cough 1 1 3.3
Pleural effusion 1 1 3.3
Vascular disorders All 1 1 3.3
Hypertension 1 1 3.3
Note: Each participant could have more than one disorder. %=(n/N) 100.
b
a
Abbreviation: SIRT: Selective internal radiation therapy.
(n = 10), and resection (n = 2), after a median of 6 months their study of 50 Asian patients, Woo et al. reported a CR
(range 2–19 months) . The survival rate for our patients at of 20% at a medium of 3 months after SIRT, according to
[8]
6 months was 100%, and the tumor responses demonstrated mRECIST . Similarly, Kim et al. reported a CR of 10%
[11]
a good clinical outcome consistent with other studies of and 11.1% by mRECIST at 3 and 6 months, respectively,
Asian patients with HCC at both 3 and 6 months after SIRT. for 40 Korean patients with unresectable HCC treated with
A study of 43 patients with unresectable HCC who were SIRT . Thus, we confirmed that the effectiveness in patient
[8]
treated at a single center reported CRs of 23.8% and 38.5% survival at 6 months after SIRT supports the continued use
at 3 and 6 months, respectively, after SIRT using mRECIST; of Y-90 resin microspheres for the treatment of unresectable
however, no 6-month survival rate was reported . In HCC in the Vietnamese population.
[20]

Volume 1 Issue 1 (2023) 6 https://doi.org/10.36922/arnm.0385